NCT06390930 Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
| NCT ID | NCT06390930 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shirley Ryan AbilityLab |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 22 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 22 participants in total. It began in 2025-02-01 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago * Relapse free for at least 6 months * Expanded Disability Status Scale (EDSS) ≤7 * Index finger abduction strength \<5 according to Medical Research Council Scale, or 9-Hole Peg Test score \>20 seconds in at least one hand * Stable disease modifying therapies for at least 6 months * Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening Exclusion Criteria: * Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function * Mini-Mental State Examination (MMSE) score \<24 * Modified Ashworth Scale score \>3 on elbow joint * Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg) * History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea * Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain * Pregnancy as confirmed by urine test
Contact & Investigator
Milap Sandhu
PRINCIPAL INVESTIGATOR
Shirley Ryan Ability Lab
Frequently Asked Questions
Who can join the NCT06390930 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06390930 currently recruiting?
Yes, NCT06390930 is actively recruiting participants. Contact the research team at rkalvakota@sralab.org for enrollment information.
Where is the NCT06390930 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06390930 clinical trial?
NCT06390930 is sponsored by Shirley Ryan AbilityLab. The principal investigator is Milap Sandhu at Shirley Ryan Ability Lab. The trial plans to enroll 22 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.